But it is worth noting that previous studies also found that the GC-1 administration, at the same time of improving liver disease model, leads to fasting blood sugar and insulin resistance to the model rats, prompted the complex relationship between TR activation and insulin sensitivity, which indicated the importance of considering the adverse effects due to insulin sensitivity when noticing the TR agonists which may be valuable in the treatment of NAFLD [109,110]. Here, INS is linked to metabolic dysfunction-associated steatotic liver disease.